

# David B Clifford

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/344162/publications.pdf>

Version: 2024-02-01

251  
papers

21,579  
citations

13068

68  
h-index

10127

140  
g-index

256  
all docs

256  
docs citations

256  
times ranked

13883  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus. <i>Brain</i> , 2022, 145, 2206-2213.	3.7	1
2	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	1.4	16
3	Post-acute sensory neurological sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: the COVID-PN observational cohort study. <i>Pain</i> , 2022, 163, 2398-2410.	2.0	8
4	The CSF in neurosarcoidosis contains consistent clonal expansion of CD8 T cells, but not CD4 T cells. <i>Journal of Neuroimmunology</i> , 2022, 367, 577860.	1.1	6
5	Leukoencephalopathy with calcifications and cysts: Genetic and phenotypic spectrum. <i>American Journal of Medical Genetics, Part A</i> , 2021, 185, 15-25.	0.7	15
6	Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 12-20.	2.9	25
7	Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. <i>Arthritis Care and Research</i> , 2021, 73, 1-9.	1.5	27
8	Cohort study protocol to characterize the incidence and severity of neuropathic pain in patients with severe acute respiratory syndrome coronavirus 2 infection. <i>Pain Reports</i> , 2021, 6, e925.	1.4	6
9	IGG4-Related Disease in the Skull Base and Calvarium: A Systematic Review and Presentation of Two Cases. , 2021, 82, .		1
10	Paresthesia Predicts Increased Risk of Distal Neuropathic Pain in Older People with HIV-Associated Sensory Polyneuropathy. <i>Pain Medicine</i> , 2021, 22, 1850-1856.	0.9	3
11	Large Mitochondrial DNA Deletions in HIV Sensory Neuropathy. <i>Neurology</i> , 2021, 97, e156-e165.	1.5	5
12	Imaging Synaptic Architecture in Human Immunodeficiency Virus: Checkpoint for Brain Function?. <i>Clinical Infectious Diseases</i> , 2021, 73, 1412-1413.	2.9	0
13	IgG4-Related Disease of the Skull and Skull Base—A Systematic Review and Report of Two Cases. <i>World Neurosurgery</i> , 2021, 150, 179-196.e1.	0.7	10
14	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
15	Hope for progressive multifocal leukoencephalopathy. <i>Lancet Neurology</i> , The, 2021, 20, 589-591.	4.9	0
16	Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, e1-e48.	2.9	174
17	The devil's details: pathological correlates of progressive multifocal leukoencephalopathy magnetic resonance imaging. <i>European Journal of Neurology</i> , 2021, , .	1.7	0
18	Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, 1-8.	2.9	66

#	ARTICLE	IF	CITATIONS
19	Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities. <i>Journal of the International Neuropsychological Society</i> , 2020, 26, 147-162.	1.2	15
20	Thinking About Getting Older With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 70, 2649-2651.	2.9	0
21	Checkpoint therapy for progressive multifocal leukoencephalopathy: pointless?. <i>European Journal of Neurology</i> , 2020, 27, 2114-2116.	1.7	2
22	Interleukin-15 superagonist (N-803) treatment of PML and JCV in a postâ€“allogeneic hematopoietic stem cell transplant patient. <i>Blood Advances</i> , 2020, 4, 2387-2391.	2.5	11
23	Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration. <i>Neurotherapeutics</i> , 2020, 17, 955-965.	2.1	17
24	Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1166-1173.	1.7	12
25	Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€“Supported Network for Excellence in Neuroscience Clinical Trials. <i>JAMA Neurology</i> , 2020, 77, 755.	4.5	6
26	Herpesvirus Infections and Risk of Parkinsonâ€™s Disease. <i>Neurodegenerative Diseases</i> , 2020, 20, 97-103.	0.8	12
27	Higher iron stores and the HFE 187C>G variant delay onset of peripheral neuropathy during combination antiretroviral therapy. <i>PLoS ONE</i> , 2020, 15, e0239758.	1.1	3
28	Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. <i>Lancet HIV</i> , 2019, 6, e456-e462.	2.1	15
29	Dosing interval of natalizumab in MS. <i>Neurology</i> , 2019, 93, 655-656.	1.5	0
30	High alert!. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1685-1685.	1.4	1
31	Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. <i>Journal of the International Neuropsychological Society</i> , 2019, 25, 507-519.	1.2	28
32	Progressive multifocal leukoencephalopathy treated with nivolumab. <i>Journal of NeuroVirology</i> , 2019, 25, 284-287.	1.0	40
33	Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy. <i>Aids</i> , 2019, 33, 475-481.	1.0	44
34	Effects of comorbidity burden and age on brain integrity in HIV. <i>Aids</i> , 2019, 33, 1175-1185.	1.0	35
35	Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection. <i>Molecular Neurobiology</i> , 2019, 56, 3808-3818.	1.9	26
36	White matter damage, neuroinflammation, and neuronal integrity in HAND. <i>Journal of NeuroVirology</i> , 2019, 25, 32-41.	1.0	77

#	ARTICLE	IF	CITATIONS
37	Is successful HIV therapy a Pyrrhic victory for the brain?. Journal of Clinical Investigation, 2019, 129, 3052-3053.	3.9	2
38	Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurology, The, 2018, 17, 467-480.	4.9	147
39	Progressive multifocal leukoencephalopathy. Neurology, 2018, 90, 255-256.	1.5	2
40	Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States. Journal of the International Neuropsychological Society, 2018, 24, 163-175.	1.2	29
41	Hemochromatosis (<i>HFE</i>) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2018, 34, 942-949.	0.5	4
42	Progressive multifocal leukoencephalopathy with extended natalizumab dosing. Neurology: Clinical Practice, 2018, 8, e12-e14.	0.8	9
43	A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials. Drug Safety, 2018, 41, 807-816.	1.4	5
44	Characterization of Cellular Immune Responses in Thai Individuals With and Without HIV-Associated Neurocognitive Disorders. AIDS Research and Human Retroviruses, 2018, 34, 685-689.	0.5	7
45	Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. JAMA Neurology, 2018, 75, 1546.	4.5	247
46	Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 413-426.	1.1	26
47	HIV-associated neurocognitive disorder. Current Opinion in Infectious Diseases, 2017, 30, 117-122.	1.3	62
48	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.4	0
49	Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. Journal of Neuroinflammation, 2017, 14, 72.	3.1	30
50	Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining â€symptomaticâ€ versus â€asymptomaticâ€ HAND. Journal of NeuroVirology, 2017, 23, 67-78.	1.0	25
51	The DIANâ€TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimer's and Dementia, 2017, 13, 8-19.	0.4	230
52	A decade of natalizumab and PML: Has there been a tacit transfer of risk acceptance?. Multiple Sclerosis Journal, 2017, 23, 934-936.	1.4	4
53	JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7. Journal of NeuroVirology, 2017, 23, 141-146.	1.0	16
54	[O1â€02â€04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.4	0

#	ARTICLE	IF	CITATIONS
55	F4â€³â€²: The Dominantly Inherited Alzheimer Network Trials Unit. <i>Alzheimer's and Dementia</i> , 2016, 12, P326.	0.4	0
56	Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls. <i>Neurotherapeutics</i> , 2016, 13, 571-581.	2.1	4
57	Apolipoprotein E Î¼4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals. <i>Journal of NeuroVirology</i> , 2016, 22, 607-614.	1.0	13
58	The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 636-647.	0.5	34
59	Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. <i>Journal of NeuroVirology</i> , 2016, 22, 479-487.	1.0	26
60	Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. <i>Journal of Infectious Diseases</i> , 2016, 213, 1065-1073.	1.9	31
61	Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. <i>Journal of NeuroVirology</i> , 2016, 22, 170-178.	1.0	112
62	Lower CSF A? is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. <i>Current HIV Research</i> , 2016, 14, 324-330.	0.2	4
63	Nemesis of neglected neurosarcoidosis. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 947-948.	1.7	3
64	Neurological immune reconstitution inflammatory response. <i>Current Opinion in Neurology</i> , 2015, 28, 295-301.	1.8	29
65	Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. <i>Pain</i> , 2015, 156, 731-739.	2.0	31
66	Factors Associated With the Onset and Persistence of Postâ€“Lumbar Puncture Headache. <i>JAMA Neurology</i> , 2015, 72, 325.	4.5	59
67	Association between brain volumes and HAND in cART-naÃ“ve HIV+ individuals from Thailand. <i>Journal of NeuroVirology</i> , 2015, 21, 105-112.	1.0	18
68	Patterns of peripheral neuropathy in ART-naÃ“ve patients initiating modern ART regimen. <i>Journal of NeuroVirology</i> , 2015, 21, 210-218.	1.0	17
69	Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. <i>Clinical Infectious Diseases</i> , 2015, 61, 1476-1484.	2.9	27
70	Reply to Haddow, et al.. <i>Clinical Infectious Diseases</i> , 2015, 60, 1442-3.	2.9	0
71	Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2015, 21, 637-644.	1.0	80
72	Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. <i>Neurology</i> , 2015, 84, 241-250.	1.5	40

#	ARTICLE	IF	CITATIONS
73	Whipple's Disease Masquerades as Dementia With Lewy Bodies. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 85-89.	0.6	7
74	CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. <i>Journal of NeuroVirology</i> , 2015, 21, 559-567.	1.0	36
75	Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 473-480.	2.9	326
76	Progressive multifocal leukoencephalopathy therapy. <i>Journal of NeuroVirology</i> , 2015, 21, 632-636.	1.0	37
77	Genetic Variation in Iron Metabolism Is Associated with Neuropathic Pain and Pain Severity in HIV-Infected Patients on Antiretroviral Therapy. <i>PLoS ONE</i> , 2014, 9, e103123.	1.1	29
78	Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. <i>Journal of NeuroVirology</i> , 2014, 20, 620-626.	1.0	24
79	Brain morphometric correlates of metabolic variables in HIV: the CHARTER study. <i>Journal of NeuroVirology</i> , 2014, 20, 603-611.	1.0	11
80	The relationship of CPE to HIV dementia. <i>Neurology</i> , 2014, 83, 109-110.	1.5	10
81	The Cerebrospinal Fluid HIV Risk Score for Assessing Central Nervous System Activity in Persons With HIV. <i>American Journal of Epidemiology</i> , 2014, 180, 297-307.	1.6	35
82	Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. <i>Neurology</i> , 2014, 82, 2055-2062.	1.5	255
83	Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. <i>Journal of NeuroVirology</i> , 2014, 20, 304-308.	1.0	14
84	Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS: Experience With the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Cohort. <i>Journal of HIV/AIDS and Social Services</i> , 2014, 13, 8-25.	0.7	6
85	Randomized Trial of Central Nervous System Targeted Antiretrovirals for HIV-Associated Neurocognitive Disorder. <i>Clinical Infectious Diseases</i> , 2014, 58, 1015-1022.	2.9	110
86	Neuroinfectious disease. <i>Neurology: Clinical Practice</i> , 2014, 4, 187-189.	0.8	0
87	Bacterial Brain Abscess. <i>Neurohospitalist, The</i> , 2014, 4, 196-204.	0.3	122
88	FTS-03-03: THE DIAN-TU. , 2014, 10, P247-P247.		0
89	Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. <i>Journal of NeuroVirology</i> , 2013, 19, 393-401.	1.0	38
90	A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. <i>Journal of NeuroVirology</i> , 2013, 19, 351-358.	1.0	138

#	ARTICLE	IF	CITATIONS
91	Tumefactive demyelination in a patient with human immunodeficiency virus. <i>Journal of NeuroVirology</i> , 2013, 19, 265-269.	1.0	3
92	Susac syndrome in a patient with human immunodeficiency virus infection. <i>Journal of NeuroVirology</i> , 2013, 19, 270-273.	1.0	3
93	Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. <i>Journal of NeuroVirology</i> , 2013, 19, 137-143.	1.0	19
94	Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. <i>Journal of NeuroVirology</i> , 2013, 19, 150-156.	1.0	57
95	The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons. <i>Journal of NeuroVirology</i> , 2013, 19, 109-116.	1.0	54
96	HIV-associated neurocognitive disorder. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 976-986.	4.6	501
97	Natalizumab. <i>JAMA Neurology</i> , 2013, 70, 172.	4.5	108
98	Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. <i>Journal of NeuroVirology</i> , 2013, 19, 557-564.	1.0	45
99	Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 684-689.	1.3	34
100	Etravirine in CSF is highly protein bound. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1161-1168.	1.3	25
101	CNS Immune Reconstitution Inflammatory Syndrome in the Setting of HIV Infection, Part 2: Discussion of Neuro Immune Reconstitution Inflammatory Syndrome with and without Other Pathogens. <i>American Journal of Neuroradiology</i> , 2013, 34, 1308-1318.	1.2	39
102	CNS Immune Reconstitution Inflammatory Syndrome in the Setting of HIV Infection, Part 1: Overview and Discussion of Progressive Multifocal Leukoencephalopathy Immune Reconstitution Inflammatory Syndrome and Cryptococcal Immune Reconstitution Inflammatory Syndrome. <i>American Journal of Neuroradiology</i> , 2013, 34, 1297-1307.	1.2	65
103	PML diagnostic criteria. <i>Neurology</i> , 2013, 80, 1430-1438.	1.5	574
104	Experience and Challenges Presented by a Multicenter Crossover Study of Combination Analgesic Therapy for the Treatment of Painful HIV-Associated Polyneuropathies. <i>Pain Medicine</i> , 2013, 14, 1039-1047.	0.9	23
105	HIV DNA Reservoir Increases Risk for Cognitive Disorders in cART-Naïve Patients. <i>PLoS ONE</i> , 2013, 8, e70164.	1.1	82
106	Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1985-1989.	1.4	14
107	Diagnosing Symptomatic HIV-Associated Neurocognitive Disorders: Self-Report <i>versus</i> Performance-Based Assessment of Everyday Functioning. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 79-88.	1.2	99
108	A Randomized, Double-Blind, Controlled Study of NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-Associated Distal Sensory Polyneuropathy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 126-133.	0.9	82

#	ARTICLE	IF	CITATIONS
109	<sup>11</sup>C-PiB Imaging of Human Immunodeficiency Virus-Associated Neurocognitive Disorder. Archives of Neurology, 2012, 69, 72.	4.9	72
110	Relationship of Medication Management Test-Revised (MMT-R) Performance to Neuropsychological Functioning and Antiretroviral Adherence in Adults with HIV. AIDS and Behavior, 2012, 16, 2286-2296.	1.4	34
111	HIV peripheral neuropathy progression: protection with glucose-lowering drugs?. Journal of NeuroVirology, 2012, 18, 428-433.	1.0	16
112	Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. Journal of NeuroVirology, 2012, 18, 511-520.	1.0	24
113	Health-Related Quality of Life 'Well-Being' in HIV Distal Neuropathic Pain is More Strongly Associated with Depression Severity than with Pain Intensity. Psychosomatics, 2012, 53, 380-386.	2.5	40
114	Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. Journal of NeuroVirology, 2012, 18, 81-90.	1.0	15
115	Antiepileptic drug selection for people with HIV/AIDS: Evidence-based guidelines from the ILAE and AAN. Epilepsia, 2012, 53, 207-214.	2.6	47
116	Lifetime suicidal ideation and attempt are common among HIV+ individuals. Journal of Affective Disorders, 2012, 136, 993-999.	2.0	75
117	Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 505-522.	0.8	143
118	Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. Journal of Clinical Virology, 2011, 52, 328-332.	1.6	11
119	Family History of Dementia Predicts Worse Neuropsychological Functioning Among HIV-Infected Persons. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 316-323.	0.9	10
120	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, The, 2011, 10, 745-758.	4.9	247
121	Performances on the CogState and Standard Neuropsychological Batteries Among HIV Patients Without Dementia. AIDS and Behavior, 2011, 15, 1902-1909.	1.4	52
122	HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of NeuroVirology, 2011, 17, 3-16.	1.0	1,327
123	Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals. Journal of NeuroVirology, 2011, 17, 17-25.	1.0	26
124	Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa. Journal of NeuroVirology, 2011, 17, 166-175.	1.0	29
125	Clinical factors related to brain structure in HIV: the CHARTER study. Journal of NeuroVirology, 2011, 17, 248-57.	1.0	158
126	Progressive multifocal leukoencephalopathy in transplant recipients. Annals of Neurology, 2011, 70, 305-322.	2.8	152



#	ARTICLE	IF	CITATIONS
127	Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 354-357.	1.3	82
128	JC Virus Antibody and Viremia as Predictors of Progressive Multifocal Leukoencephalopathy in Human Immunodeficiency Virus-1â€“Infected Individuals. <i>Clinical Infectious Diseases</i> , 2011, 53, 711-715.	2.9	52
129	Peripheral neuropathy in HIV: prevalence and risk factors. <i>Aids</i> , 2011, 25, 919-928.	1.0	171
130	Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis. <i>Archives of Neurology</i> , 2011, 68, 1156.	4.9	244
131	Role of CD4 <sup>+</sup> and CD8 <sup>+</sup> T-Cell Responses against JC Virus in the Outcome of Patients with Progressive Multifocal Leukoencephalopathy (PML) and PML with Immune Reconstitution Inflammatory Syndrome. <i>Journal of Virology</i> , 2011, 85, 7256-7263.	1.5	116
132	Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 921-928.	0.6	46
133	Immune reconstitution inflammatory syndrome in natalizumab-associated PML. <i>Neurology</i> , 2011, 77, 1061-1067.	1.5	209
134	Lessons from the clinic: A case of natalizumab-associated PML. <i>Neurology</i> , 2011, 76, 574-574.	1.5	26
135	Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2011, 33, 326-334.	0.8	17
136	Vicriviroc and Peripheral Neuropathy: Results from AIDS Clinical Trials Group 5211. <i>HIV Clinical Trials</i> , 2010, 11, 51-58.	2.0	4
137	NeuroAIDS in Africa. <i>Journal of NeuroVirology</i> , 2010, 16, 189-202.	1.0	42
138	Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. <i>Lancet Neurology</i> , The, 2010, 9, 438-446.	4.9	604
139	PML: underdiagnosed in MS patients on natalizumab â€“ Authors' reply. <i>Lancet Neurology</i> , The, 2010, 9, 564-565.	4.9	0
140	Viral Escape in Cerebrospinal Fluidâ€”An Achilles Heel of HIV Therapy?. <i>Journal of Infectious Diseases</i> , 2010, 202, 1768-1769.	1.9	11
141	African Mitochondrial DNA Subhaplogroups and Peripheral Neuropathy during Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 201, 1703-1707.	1.9	38
142	Continued High Prevalence and Adverse Clinical Impact of Human Immunodeficiency Virusâ€“Associated Sensory Neuropathy in the Era of Combination Antiretroviral Therapy. <i>Archives of Neurology</i> , 2010, 67, 552.	4.9	347
143	Early changes on electroencephalography in natalizumab-associated progressive multifocal leukoencephalopathy. <i>Multiple Sclerosis Journal</i> , 2010, 16, 749-753.	1.4	8
144	Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5156-5160.	1.4	63

#	ARTICLE	IF	CITATIONS
145	Pregabalin for painful HIV neuropathy. <i>Neurology</i> , 2010, 74, 413-420.	1.5	185
146	HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. <i>Neurology</i> , 2010, 75, 2087-2096.	1.5	2,036
147	Progressive multifocal leukoencephalopathy and other forms of JC virus disease. <i>Nature Reviews Neurology</i> , 2010, 6, 667-679.	4.9	191
148	Neurologic Presentations of Sarcoidosis. <i>Neurologic Clinics</i> , 2010, 28, 185-198.	0.8	47
149	Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab. <i>New England Journal of Medicine</i> , 2009, 361, 1075-1080.	13.9	190
150	Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s). <i>HIV Clinical Trials</i> , 2009, 10, 343-355.	2.0	100
151	CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. <i>Neurology</i> , 2009, 73, 1982-1987.	1.5	156
152	Determinants of survival in progressive multifocal leukoencephalopathy. <i>Neurology</i> , 2009, 73, 1551-1558.	1.5	154
153	HIV Subtype D Is Associated with Dementia, Compared with Subtype A, in Immunosuppressed Individuals at Risk of Cognitive Impairment in Kampala, Uganda. <i>Clinical Infectious Diseases</i> , 2009, 49, 780-786.	2.9	129
154	HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 455-461.	2.0	47
155	Natalizumab and PML: a risky business?. <i>Gut</i> , 2008, 57, 1347-1349.	6.1	14
156	Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System. <i>Archives of Neurology</i> , 2008, 65, 65.	4.9	777
157	The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. <i>Pharmacogenomics Journal</i> , 2008, 8, 71-77.	0.9	56
158	Simplification of the Research Diagnosis of HIV-Associated Sensory Neuropathy. <i>HIV Clinical Trials</i> , 2008, 9, 434-439.	2.0	15
159	HIV-associated neurocognitive disease continues in the antiretroviral era. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2008, 16, 94-8.	2.9	51
160	Frequency and Phenotype of JC Virus-Specific CD8 + T Lymphocytes in the Peripheral Blood of Patients with Progressive Multifocal Leukoencephalopathy. <i>Journal of Virology</i> , 2007, 81, 3361-3368.	1.5	59
161	Factors in AIDS Dementia Complex Trial Design: Results and Lessons from the Abacavir Trial. <i>PLOS Clinical Trials</i> , 2007, 2, e13.	3.5	46
162	Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. <i>HIV Clinical Trials</i> , 2007, 8, 437-446.	2.0	30

#	ARTICLE	IF	CITATIONS
163	Histoplasmosis: Isolated central nervous system infection with <i>Histoplasma capsulatum</i> in a patient with AIDS. <i>Clinical Neurology and Neurosurgery</i> , 2007, 109, 176-181.	0.6	17
164	HIV-associated cognitive impairment in sub-Saharan Africa—the potential effect of clade diversity. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 436-443.	2.7	49
165	A Randomized Trial Evaluating Prosapectid, for HIV-Associated Sensory Neuropathies: Use of an Electronic Diary to Record Neuropathic Pain. <i>PLoS ONE</i> , 2007, 2, e551.	1.1	36
166	HIV-associated neuromuscular weakness syndrome in Brazil: report of the two first cases. <i>Arquivos De Neuro-Psiquiatria</i> , 2007, 65, 848-851.	0.3	5
167	Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. <i>Lancet Neurology</i> , The, 2007, 6, 431-441.	4.9	331
168	Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. <i>Journal of NeuroVirology</i> , 2007, 13, 67-72.	1.0	45
169	The Role of Cohort Studies in Drug Development: Clinical Evidence of Antiviral Activity of Serotonin Reuptake Inhibitors and HMG-CoA Reductase Inhibitors in the Central Nervous System. <i>Journal of NeuroImmune Pharmacology</i> , 2007, 2, 120-127.	2.1	38
170	Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. <i>Aids</i> , 2006, 20, 1503-1513.	1.0	53
171	Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study. <i>Clinical Infectious Diseases</i> , 2006, 42, 401-407.	2.9	208
172	Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy. <i>New England Journal of Medicine</i> , 2006, 354, 924-933.	13.9	744
173	The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. <i>Aids</i> , 2005, 19, S64-S71.	1.0	65
174	Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. <i>Aids</i> , 2005, 19, 1341-1349.	1.0	129
175	Clinical validation of the NeuroScreen. <i>Journal of NeuroVirology</i> , 2005, 11, 503-511.	1.0	65
176	Pharmacogenetics of Long-Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study. <i>Journal of Infectious Diseases</i> , 2005, 192, 1931-1942.	1.9	232
177	Genotyping of <i>Toxoplasma gondii</i> Strains from Immunocompromised Patients Reveals High Prevalence of Type I Strains. <i>Journal of Clinical Microbiology</i> , 2005, 43, 5881-5887.	1.8	185
178	Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals. <i>Annals of Internal Medicine</i> , 2005, 143, 714.	2.0	226
179	HIV-associated neuromuscular weakness syndrome. <i>Aids</i> , 2004, 18, 1403-1412.	1.0	53
180	Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. <i>Aids</i> , 2004, 18, 2391-400.	1.0	429

#	ARTICLE	IF	CITATIONS
181	Challenges for Clinical Trials to Treat Progressive Multifocal Leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2003, 9, 68-72.	1.0	5
182	Effects of fructose-1,6-bisphosphate on morphological and functional neuronal integrity in rat hippocampal slices during energy deprivation. <i>Neuroscience</i> , 2003, 116, 465-475.	1.1	13
183	Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 59-62.	1.4	61
184	The Evolving Face of Human Immunodeficiency Virus-Related Progressive Multifocal Leukoencephalopathy: Defining a Consensus Terminology. <i>Journal of NeuroVirology</i> , 2003, 9, 88-92.	1.0	11
185	A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. <i>Aids</i> , 2002, 16, 1791-1797.	1.0	183
186	A randomized clinical trial of CPI-1189 for HIV-associated cognitiveâ€“motor impairment. <i>Neurology</i> , 2002, 59, 1568-1573.	1.5	77
187	AIDS dementia. <i>Medical Clinics of North America</i> , 2002, 86, 537-550.	1.1	26
188	Challenges for clinical trials on progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2001, 7, 350-352.	1.0	2
189	HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. <i>Aids</i> , 2001, 15, 747-751.	1.0	47
190	BK Virus: A Clinical Review. <i>Clinical Infectious Diseases</i> , 2001, 33, 191-202.	2.9	237
191	Human Immunodeficiency Virusâ€“Associated Dementia. <i>Archives of Neurology</i> , 2000, 57, 321.	4.9	56
192	HIV-Associated Dementia. <i>Science</i> , 2000, 288, 439d-439.	6.0	54
193	Opportunistic Viral Infections in the Setting of Human Immunodeficiency Virus. <i>Seminars in Neurology</i> , 1999, 19, 185-192.	0.5	22
194	HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. <i>Neurology</i> , 1999, 52, 623-623.	1.5	245
195	Notes Progressive Multifocal Leukoencephalopathy in Patients with AIDS Receiving Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 1999, 28, 1152-1154.	2.9	88
196	Central neurologic complications of HIV infection. <i>Current Infectious Disease Reports</i> , 1999, 1, 187-191.	1.3	6
197	Focal brain lesions in people with HIV. <i>Current Treatment Options in Neurology</i> , 1999, 1, 167-172.	0.7	6
198	Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 1999, 45, 816-820.	2.8	102

#	ARTICLE	IF	CITATIONS
199	Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. <i>Aids</i> , 1999, 13, 1677-1685.	1.0	131
200	Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. <i>American Journal of Neuroradiology</i> , 1999, 20, 1896-906.	1.2	108
201	Failure of Cytarabine in Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 1998, 338, 1345-1351.	13.9	343
202	NEUROLOGIC COMPLICATIONS OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION. <i>Neurologist</i> , 1998, 4, 54-65.	0.4	4
203	Stable neurological function in subjects treated with 23-dideoxyinosine. <i>Journal of NeuroVirology</i> , 1997, 3, 233-240.	1.0	9
204	Nitric oxide inhibitors attenuate ischemic degeneration in the CA1 region of rat hippocampal slices. <i>Neuroscience Letters</i> , 1996, 210, 157-160.	1.0	24
205	Cytomegalovirus Encephalitis. <i>Annals of Internal Medicine</i> , 1996, 125, 577.	2.0	191
206	Magnetic resonance brain imaging lacks sensitivity for AIDS associated cytomegalovirus encephalitis. <i>Journal of NeuroVirology</i> , 1996, 2, 397-403.	1.0	34
207	Neurologic opportunistic infections. <i>Current Opinion in Neurology</i> , 1995, 8, 175-178.	1.8	4
208	Level of Cytomegalovirus (CMV) DNA in Cerebrospinal Fluid of Subjects with AIDS and CMV Infection of the Central Nervous System. <i>Journal of Infectious Diseases</i> , 1995, 172, 527-531.	1.9	110
209	Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. <i>Journal of Clinical Microbiology</i> , 1995, 33, 1580-1583.	1.8	103
210	Concanavalin a enhances excitatory synaptic transmission in cultured rat hippocampal neurons. <i>Synapse</i> , 1993, 13, 94-97.	0.6	15
211	Blockade of ionotropic quisqualate receptor desensitization in rat hippocampal neurons by wheatgerm agglutinin and other lectins. <i>Neuroscience</i> , 1993, 52, 35-44.	1.1	12
212	Long-term potentiation during whole-cell recording in rat hippocampal slices. <i>Neuroscience</i> , 1993, 53, 39-47.	1.1	57
213	Electrophysiological properties of identified postnatal rat hippocampal pyramidal neurons in primary culture. <i>Developmental Brain Research</i> , 1993, 71, 19-26.	2.1	15
214	White matter lesions and cerebral atrophy on MR images in patients with and without AIDS dementia complex.. <i>American Journal of Roentgenology</i> , 1993, 161, 177-181.	1.0	44
215	Use of polymerase chain reaction to demonstrate cytomegalovirus DNA in CSF of patients with human immunodeficiency virus infection. <i>Neurology</i> , 1993, 43, 75-75.	1.5	49
216	Inhibition of long-term potentiation by NMDA-mediated nitric oxide release. <i>Science</i> , 1992, 257, 1273-1276.	6.0	226

#	ARTICLE	IF	CITATIONS
217	Management of Neurologic Opportunistic Disorders in Human Immunodeficiency Virus Infection. <i>Seminars in Neurology</i> , 1992, 12, 28-33.	0.5	2
218	Low concentrations of inhibit the induction of long-term potentiation in rat hippocampal slices. <i>Neuroscience Letters</i> , 1992, 137, 245-248.	1.0	57
219	Nitric oxide inhibitors attenuate excitotoxicity in rat hippocampal slices. <i>Neuroscience Letters</i> , 1992, 135, 227-230.	1.0	183
220	Norepinephrine reverses inhibition of long-term potentiation in rat hippocampal slices. <i>Neuroscience Letters</i> , 1992, 142, 163-166.	1.0	21
221	Blockade of ionotropic quisqualate receptor desensitization by wheat germ agglutinin in cultured postnatal rat hippocampal neurons. <i>Journal of Neurophysiology</i> , 1992, 68, 1917-1929.	0.9	11
222	Wheat germ agglutinin enhances EPSCs in cultured postnatal rat hippocampal neurons by blocking ionotropic quisqualate receptor desensitization. <i>Journal of Neurophysiology</i> , 1992, 68, 1930-1938.	0.9	21
223	Nicotinic acetylcholine currents in cultured postnatal rat hippocampal neurons. <i>Molecular Pharmacology</i> , 1992, 41, 931-6.	1.0	72
224	2-Amino-3-phosphonopropionate blocks the induction and maintenance of long-term potentiation in rat hippocampal slices. <i>Neuroscience Letters</i> , 1991, 122, 187-190.	1.0	90
225	Characterization of quisqualate receptor desensitization in cultured postnatal rat hippocampal neurons. <i>Journal of Neuroscience</i> , 1991, 11, 3430-3441.	1.7	41
226	Ocular motor abnormalities in human immunodeficiency virus infection. <i>Annals of Neurology</i> , 1991, 30, 130-138.	2.8	22
227	Effects of bromowillardiine and willardiine on non-N-methyl-D-aspartate receptors in postnatal rat hippocampal neurons. <i>Molecular Pharmacology</i> , 1991, 40, 45-51.	1.0	8
228	Ototoxicity associated with dideoxycytidine. <i>Lancet, The</i> , 1990, 335, 1106.	6.3	24
229	Lithium enhances neuronal muscarinic excitation by presynaptic facilitation. <i>Neuroscience</i> , 1990, 38, 457-468.	1.1	23
230	Blockade of desensitization augments quisqualate excitotoxicity in hippocampal neurons. <i>Neuron</i> , 1990, 5, 61-66.	3.8	67
231	Serial studies of serum interleukin-2 in chronic progressive multiple sclerosis patients: occurrence of "bursts" and effect of cyclosporine. <i>Journal of Neuroimmunology</i> , 1990, 28, 9-14.	1.1	21
232	Ketamine, Phencyclidine, and MK-801 Protect Against Kainic Acid-Induced Seizure-Related Brain Damage. <i>Epilepsia</i> , 1990, 31, 382-390.	2.6	201
233	Glycine antagonists block the induction of long-term potentiation in CA1 of rat hippocampal slices. <i>Neuroscience Letters</i> , 1990, 112, 251-256.	1.0	25
234	Neurological aspects of AIDS. <i>Missouri Medicine</i> , 1990, 87, 141-4.	0.3	0

#	ARTICLE	IF	CITATIONS
235	Osmotic Demyelination Syndrome. Archives of Neurology, 1989, 46, 343.	4.9	30
236	Calcium influx through channels activates a potassium current in postnatal rat hippocampal neurons. Neuroscience Letters, 1989, 99, 293-299.	1.0	59
237	Complex responses activated by ibotenate in postnatal rat hippocampal neurons. Brain Research, 1989, 494, 193-197.	1.1	6
238	Convulsant Î³-butyrolactones block GABA currents in cultured chick spinal cord neurons. Brain Research, 1989, 484, 102-110.	1.1	7
239	Î±-Substituted thiobutyrolactones potentiate GABA currents in voltage-clamped chick spinal cord neurons. Neuroscience Letters, 1988, 87, 133-138.	1.0	13
240	Hyponatremia and the brain. American Family Physician, 1988, 38, 119-24.	0.1	1
241	The functional anatomy and pathology of lithium-pilocarpine and high-dose pilocarpine seizures. Neuroscience, 1987, 23, 953-968.	1.1	336
242	AIDS and the brain. American Family Physician, 1987, 36, 101-6.	0.1	27
243	Acute Effects of Lithium on Hippocampal Kindled Seizures. Epilepsia, 1985, 26, 689-692.	2.6	23
244	Acute effects of antidepressants on hippocampal seizures. Annals of Neurology, 1985, 18, 692-697.	2.8	31
245	Treatment of pain with antidepressants. American Family Physician, 1985, 31, 181-5.	0.1	14
246	Pain in Multiple Sclerosis. Archives of Neurology, 1984, 41, 1270-1272.	4.9	182
247	Seizures and pregnancy. American Family Physician, 1984, 29, 271-5.	0.1	2
248	Tetrahydrocannabinol for tremor in multiple sclerosis. Annals of Neurology, 1983, 13, 669-671.	2.8	170
249	Neurophysiologic effects of folate compounds in hippocampus, in vitro. Brain Research, 1983, 266, 209-216.	1.1	8
250	Thymectomy in multiple sclerosis. Two preliminary trials. Journal of Thoracic and Cardiovascular Surgery, 1983, 85, 88-93.	0.4	2
251	Progressive Multifocal Leukoencephalopathy in the Era of HAART. , 0, , 375-382.		1